尿液蛋白检测:胰腺癌早期检测的新曙光
2015/08/05
近日,英国和西班牙的科学家研发了一种新的测试方法,希望能更早地检测到胰腺癌并提供更及时的治疗。科学家发现胰腺癌患者尿液中LYVE1、REG1A和TFF1三种蛋白含量最为显著,或可作为识别胰腺癌的蛋白信号。


胰腺癌是致死率极高的一种癌症。每100位胰腺癌患者中,只有3位可以存活5年以上,而且,近40年来,此癌症的存活率并没有提高。大多数的胰腺癌患者确诊的时间比较晚,80%的患者在术后有复发现象。

目前关于胰腺癌的研究数据表明,早期检测可以挽救更多的生命,病人可根据早期诊断结果获取手术的资格。通常患者被诊断出胰腺癌时已处在终端阶段,如果能在二阶段诊断出胰腺癌,那存活率会是20%,若能在第一阶段诊断,那么生存率会增加到60%。因此胰腺癌的早期诊断十分有必要!科学家也致力于胰腺癌早期诊断的研究。

Nature:胞外体蛋白或有助诊断早期胰腺癌

今年6月份,德克萨斯大学MD安德森癌症中心研究人员发现一种胞外体蛋白可能是标准诊断胰腺癌的生物标志物。研究人员在250位胰腺癌患者的血清中检测到GPC1+crexos的绝对特异性和敏感性,这有助于从早期或者晚期胰腺癌中区分出慢性胰腺癌。该研究结果发表在《Nature》上。[详细……]

尿液“蛋白信号”或成为早期胰腺癌检测工具

近日,英国和西班牙的科学家研发了一种新的测试方法,希望能更早地检测到胰腺癌并提供更及时的治疗。该结果发表在《 Clinical Cancer Research》杂志上。

研究人员采集了大约500个尿液样本,其中200份来自胰腺癌患者,92份来自慢性胰腺炎患者,87份来自健康的志愿者,其余的样本来自良性和恶性肝脏和胆囊患者。研究人员在尿液样本中发现了1500种蛋白质,其中LYVE1、REG1A和TFF1三种蛋白在胰腺癌患者尿液中含量最高,而在慢性胰腺炎患者的尿液中含量更低些。这三种蛋白可作为识别该疾病的“蛋白质信号”,研究发现该“蛋白质信号”具有90%的准确率。

英国癌症中心Fiona Osgun表示,该研究结果是否能作为胰腺癌的早期检测工具还有待进一步研究。但这样的研究是十分有必要的,只要有一线希望可以提高胰腺癌的生存率,我们都不应该放弃,方法的创新是十分有必要的。

查看更多
  • Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

    Purpose: Noninvasive biomarkers for early detection of pancreatic ductal adenocarcinoma (PDAC) are currently not available. Here, we aimed to identify a set of urine proteins able to distinguish patients with early-stage PDAC from healthy individuals. Experimental design: Proteomes of 18 urine samples from healthy controls, chronic pancreatitis, and patients with PDAC (six/group) were assayed using GeLC/MS/MS analysis. The selected biomarkers were subsequently validated with ELISA assays using multiple logistic regression applied to a training dataset in a multicenter cohort comprising 488 urine samples. Results: LYVE-1, REG1A, and TFF1 were selected as candidate biomarkers. When comparing PDAC (n = 192) with healthy (n = 87) urine specimens, the resulting areas under the receiver-operating characteristic curves (AUC) of the panel were 0.89 [95% confidence interval (CI), 0.84–0.94] in the training (70% of the data) and 0.92 (95% CI, 0.86–0.98) in the validation (30% of the data) datasets. When comparing PDAC stage I–II (n = 71) with healthy urine specimens, the panel achieved AUCs of 0.90 (95% CI, 0.84–0.96) and 0.93 (95% CI, 0.84–1.00) in the training and validation datasets, respectively. In PDAC stage I–II and healthy samples with matching plasma CA19.9, the panel achieved a higher AUC of 0.97 (95% CI, 0.94–0.99) than CA19.9 (AUC = 0.88; 95% CI, 0.81–0.95, P = 0.005). Adding plasma CA19.9 to the panel increased the AUC from 0.97 (95% CI, 0.94–0.99) to 0.99 (95% CI, 0.97–1.00, P = 0.04), but did not improve the comparison of stage I–IIA PDAC (n = 17) with healthy urine. Conclusions: We have established a novel, three-protein biomarker panel that is able to detect patients with early-stage pancreatic cancer in urine specimens.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test